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If a genetic disease affects less than 5 in 10,000 people, it is categorised as a rare or orphan disease. 
This branding to a ͚rare͛ or ͚orphaŶ͛ status is misleading in some regards. Due to the stigma of being 
͚rare͛, research funders often consider them to be of a lesser priority. You can of course understand 
their pragmatic ǀieǁ poiŶt: ͚oŶly a small percentage of people will benefit from research on rare 
diseases; therefore they will have less overall impact͛. Consequently, funding opportunities become 
restrictive and research progress is slow. This lack of forward research momentum has hampered 
our understanding of many rare genetic disorders. It is estimated that one in 25 children is affected 
with a genetic disorder. So, if you consider them as a collective, they are not so rare. Thankfully, 
perception of rare diseases has changed dramatically, mainly due to the perseverance of rare 
disease charities and families affected by these disorders. In fact, the research landscape of rare 
diseases is now in a much better place. This review series highlights the unique opportunity that 
these diseases present. Patients with rare diseases become in essence a human genetic model, 
which allows for very detailed research into new signalling mechanisms linked to human health and 
disease.  
Some genetic disorders are apparent at birth while others are typically diagnosed early in 
childhood. The cover page of this review series illustrates a cartoon of a child with a rare genetic 
disorder being led by her parent. The cover page has a rough sketch of a signalling pathway that has 
been delineated through research on several rare genetic disorders, of which will be further 
discussed in this review series. The Đhild͛s represeŶtatioŶ of therapy toǁards a tuŵour is iŶdiĐatiǀe 
of the current success story on Tuberous Sclerosis Complex (TSC). Through working closely with 
patient families with TSC, research breakthroughs were made that revealed the molecular 
mechanism behind their tumour predisposition. Our understanding of TSC and mammalian target of 
rapamycin (mTOR) will be further discussed by Dodd & Dunlop [1]. As well as being predisposed to 
tumours, neurological complications are also associated with TSC, which will be discussed in the 
review by Tee et al. [2].  
The signalling pathway upstream of TSC and mTOR is represented in the cover page and is 
closely associated with other tumour predisposition genetic diseases. CoǁdeŶ͛s disease, where the 
LKB1 gene is mutated is reviewed in depth by Shorning & Clarke [3]. They highlight the importance 
of studying genetic models and then discuss how they have increased our fundamental 
understanding of mechanisms linked to tumour biology. At the top of the depicted signalling 
pathway, Leslie & Longy [4] describe Peutz-Jeghers syndrome, which is caused by mutations in PTEN, 
a lipid phosphatase that directly opposes the insulin stimulated phosphoinositide 3-kinase signalling 
pathway. Rad & Tee [5] then discuss neurofibromatosis, where patients have mutations in 
neurofibromin. While neurofibromin is well characterised for its ability to repress cell proliferation 
through inhibition of the Ras small G protein, neurofibromin has many other interesting tumour 
suppressor functions that are closely linked to malignancy. Another closely related tumour 
predisposition syndrome is Birt-Hogg-Dubé (BHD). The molecular mechanism behind why BHD 
patients are at increased risk of spontaneous pneumothorax is currently unclear. The review by 
Kennedy et al. describes the lung pathology related to BHD and a stretch hypothesis leading to the 
formation of cysts and then lung collapse [6]. 
The review on alkaptonuria (also known as black bone disease) is described by Gallagher et 
al. [7], where these patients are unable to process phenylalanine and tyrosine leading to acid 
accumulation in their bones and tissue. Research breakthroughs of alkaptonuria have contributed to 
our ͚fuŶdaŵeŶtal͛ uŶderstaŶdiŶg of the pathogeŶesis of osteoarthritis, which mostly effects the 
aging population. Here in this review, they also eloquently describe the history of iconic medical 
researchers who valued rare diseases in the study of biomedical sciences. 
IŶ the reǀieǁ eŶtitled ͚MakiŶg the iŶǀisiďle ǀisiďle͛ Prof. Maurice van Steensel then describes 
how genetic skin diseases allows for the study of human biology on the canvas of the skin [8]. 
Through genetic analysis and research of skin disorders much progress has been made in our basic 
understanding of skin pigmentation, a topic covered in this review. 
I hope you enjoy this review series on several prominent genetic disorders. While research in 
these research topics will undoubtedly led to advances in health care, there are many more 
disorders that are in desperate need for curious minds and research funding. By researching new 
mechanisms of pathology in rare genetic disorders, we enhance our overall understanding of more 
common disorders or diseases within the general population. 
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